Xofigo (Radium – 223) for Treatment of Prostate Cancer


If you have any questions, to schedule a consultation or if you need a second opinion, please contact us or call: 646-663-5515


Xofigo for Treatment of Metastatic CRPC with Bony Metastasis.

On May 15, 2013, the U.S. Food and Drug Administration (FDA) approved Radium-223 dichloride to treat men with symptomatic metastatic castration-resistant prostate cancer that has spread to bones but not to other organs.

Xofigo is a radiopharmaceutical has been shown to be beneficial for men with metastatic prostate cancer. Xofigo leads to decreased pain, improved quality of life, and improved survival.


If you have any questions, to schedule a consultation or if you need a second opinion, please contact us or call: 646-663-5515


 

Top